01 Do I need to make money to go public?02 A new M&A playbook in the age of AI03 Cyber enforcement forecast post-SolarWinds decision04 Cyber diligence for IPOs with Kroll’s CISO05 The Download Quiz: Venture capital trends...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2024 include: • Life sciences VC deal value in Q1 totaled $7.8 billion, which represents a 22.1% increase in value from Q4...more
With the compliance deadline for the newly issued Item 408(b) of Regulation S-K approaching for calendar-year-end companies and the increased use by the Department of Justice and the SEC of data analytics in pursuing insider...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2023 include: • Life sciences VC deal value in Q4 2023 totaled $6.6 billion, representing a 25.0% decrease from the prior...more
Many private companies have not kept up with recent changes affecting when certain disclosures or reports may be required. That consensus, along with other takeaways, emerged in recent panel discussions at the Society for...more
The Securities and Exchange Commission (the “SEC”) has finalized its long-awaited rules regarding special purpose acquisition companies (“SPAC”). So, what are the key aspects of these rules that SPAC market participants...more
On December 19, 2023, the Fifth Circuit officially vacated the SEC’s share repurchase disclosure rules. As a result of the Court’s decision, companies will not need to comply with the now-vacated share repurchase disclosure...more
On October 31, 2023, the Fifth Circuit ruled in Chamber of Commerce of the USA v. SEC that the SEC violated the Administrative Procedure Act when it adopted enhanced share repurchase disclosure rules. The Court provided the...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include:
Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2023 include:
• Life sciences VC deal value in Q2 2023 totaled $6.7 billion across 384 deals, representing a slight...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include:
• Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include:
• Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more
2022 was a busy year in rulemaking for the Securities and Exchange Commission (SEC). As a result, there are many new disclosure requirements for companies to keep top of mind as they work through this year’s annual report,...more
1/27/2023
/ Compliance Dates ,
Corporate Governance ,
Disclosure Requirements ,
EDGAR ,
Final Rules ,
Form 10-K ,
Proxy Season ,
Proxy Statements ,
Publicly-Traded Companies ,
Regulation S-K ,
Securities and Exchange Commission (SEC)
For many insiders at a newly formed public company, a large portion of their net worth is potentially tied up in holdings of their company’s publicly-traded shares. These insiders often face challenges obtaining liquidity...more
1/19/2023
/ Capital Markets ,
Disclosure Requirements ,
Glass Lewis ,
Hedging ,
Insider Trading ,
Institutional Shareholder Services (ISS) ,
Proxy Advisors ,
Proxy Statements ,
Proxy Voting Guidelines ,
Publicly-Traded Companies ,
Regulation S-K ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2022 include:
• The industry generated $6.2 billion in deal value across 352 deals in Q3, exhibiting further quarterly...more
On Friday, October 7, 2022, the Securities and Exchange Commission (the “SEC”) reopened the public comment periods for eleven rulemaking proposals and one request for comment due to a technical error that prevented the SEC...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2022 include:
• The industry generated $8.8 billion in deal value across 362 deals in Q2, a material decline from Q1, as...more
This edition of Orrick’s life sciences publication series breaks down the key drivers of venture investment in the life sciences industry, which is on track to set all-time records this year. Key findings include: • With...more
This edition of Orrick’s life sciences publication series reviews the key drivers of venture investment in the life sciences industry, which is proceeding at a record pace thus far in 2021. Key findings include:
Investment...more
This edition of Orrick’s series of life sciences publications breaks down the record venture investment into US-based life sciences companies in 2020 and strong showing in Q1 2021. Key findings include: • US-based life...more
This edition of Orrick’s series of life sciences publications reviews fullyear 2020 data in depth to identify and summarize the key trends that shaped venture investment across the sector. 2020 was a banner period for many...more
In this edition of Orrick’s series of life sciences publications, the traditional update on broader venture market financing data is included, depicting the macro-level trends of interest. In addition, given their surge in...more
On August 31, 2020, the California State Assembly Banking and Finance Committee voted to give final legislative approval to Assembly Bill 979 (AB 979), allowing it to move forward to Governor Newsom for signature or veto on...more
Exchange Act Reports; Securities Act Filings -
On August 26, 2020, the Securities and Exchange Commission announced changes to Regulation S-K intended to modernize certain disclosures related to an issuer’s business...more
In this edition of Orrick’s series of life sciences publications, we offer a market update drawing on a variety of PitchBook datasets depicting macro trends in financing across the market, as well as a spotlight on any trends...more